RACURA ONCOLOGY

## ASX Announcement

# Racura Oncology to Present at TechKnow Invest Conference

**29 July 2026**

Racura Oncology Limited ("Racura") is pleased to advise that CEO and Managing Director, Dr Daniel Tillett will be presenting at the TechKnow Invest Conference in Sydney on 29 July 2026 at 12.30pm. The TechKnow Invest Confrence is being held at Hotel Swissotel, 68 Market Street, Sydney, Australia.

A copy of the presentation is attached to this announcement.

-ENDS-

# About Racura Oncology

Racura Oncology (ASX: RAC) is a Phase 3 clinical-stage biopharmaceutical company with a mission to silence cancer.

Racura's lead asset, (E,E)-bisantrene, is a clinically derisked small-molecule anticancer agent that primarily acts by stabilising G4-DNA and RNA structures, driving potent silencing of c-MYC, a key cancer gene dysregulated in up to 70% of all cancers. (E,E)-bisantrene has shown therapeutic activity in cancer patients and has a well-characterised safety profile. Racura's discoveries have supported composition-of-matter IP filings that, if granted, could provide up to 20 years of patent protection for (E,E)-bisantrene.

Racura is advancing RC220, its proprietary formulation of (E,E)-bisantrene, to address significant unmet need across multiple MYC-driven oncology indications. The Company's clinical programs include the Phase 3 EMILI trial in acute myeloid leukaemia, the Phase 1a/b HARNESS trial in combination with osimertinib for EGFR-mutated non-small cell lung cancer, and the Phase 1a/b CPACS trial in combination with doxorubicin, where Racura aims to deliver both anthracycline cardioprotection and enhanced anticancer activity.

Racura has collaborated with Astex, Emory University, Purdue University, MD Anderson, Sheba City of Health, UNC School of Medicine, the University of Wollongong and the University of Newcastle. Racura is actively exploring partnerships, licence agreements and potential commercial merger and acquisition opportunities to accelerate global patient access to RC220. Learn more at www.racuraoncology.com.

For questions about this announcement or previous Racura Oncology announcements, please visit our Interactive Announcements page.

Racura encourages investors to go paperless by registering their email details with the Company's share registry, Automic Registry Services, at www.automicgroup.com.au.


Release authorised by

Daniel Tillett, CEO/MD

info@racuraoncology.com

Media Contact

Cherie Hartley +61 418 737 020

cherie.hartley@irdepartment.com.au

RACURA ONCOLOGY

July 2026

# Racura Oncology

## TechKnow Invest Roadshow

**Dr Daniel Tillett, CEO & MD**

# Important notice and disclaimer

The material in this presentation has been prepared by Racura Oncology Limited (ACN 149 318 749) (Company).

THIS IS NOT A PROSPECTUS

This presentation is not a prospectus, product disclosure statement or disclosure document for the purposes of the Corporations Act 2001 (Cth) (Corporations Act). It has not been lodged with the Australian Securities and Investments Commission, or otherwise.

Statements in this presentation are made only as of the date of this presentation unless otherwise stated and the information in this presentation remains subject to change without notice. No representation or warranty, express or implied, is made as to the fairness, accuracy or completeness of the information, opinions and conclusions contained in this presentation or any other information the Company or any other person otherwise provides to you.

This presentation does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States. Any securities described in this presentation have not been, and will not be, registered under the US Securities Act of 1933, as amended (Securities Act) or the securities laws of any state or other jurisdiction of the United States and may not be offered or sold in the United States except in transactions exempt from, or not subject to, registration under the Securities Act and applicable US state securities laws. This presentation may not be released to US wire services or distributed in the United States. The distribution of this presentation in other jurisdictions outside Australia may also be restricted by law and any such restrictions should be observed.

NOT FINANCIAL PRODUCT ADVICE

No attempt has been made to independently verify the information contained in this presentation. The information in this presentation is of a general nature and does not constitute financial product advice, investment advice or any recommendation. Nothing in this presentation constitutes legal, financial, tax or other advice. The information in this presentation does not take into account your particular investment objectives, financial situation or needs, or those of any other person. You should make your own assessment of an investment in the Company and should not rely on this presentation. In all cases, you should conduct your own investigations and analysis of the financial condition, assets and liabilities, financial position and performance, profits and losses, prospects and business affairs of the Company and its business, and the contents of this presentation. You should seek legal, financial, tax and other advice appropriate to your jurisdiction.

THIS PRESENTATION DOES NOT CONSTITUTE AN OFFER OR ADVERTISEMENT

This presentation does not constitute an invitation, offer or recommendation to apply for or purchase Shares and does not contain any application form for Shares. This presentation does not constitute an advertisement for an offer or proposed offer of Shares.

NO LIABILITY

The Company has prepared this presentation based on information available to it at the time of preparation, from sources believed to be reliable and subject to the qualifications in this presentation. No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of the Company or its subsidiaries or affiliates or the directors, employees, agents, representatives or advisers of any such party, nor any other person accepts any liability for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it, including without limitation, any liability arising from fault or negligence on the part of the Company or its subsidiaries or affiliates or the directors, employees, agents, representatives or advisers of any such party.

FORWARD-LOOKING STATEMENTS

This presentation may contain forward-looking statements that are subject to risk factors associated with an oncology company. Forward looking statements can be identified by the use of forward-looking terminology, including, without limitation, the terms “believes”, “estimates”, “anticipates”, “expects”, “predicts”, “intends”, “plans”, “goals”, “targets”, “aims”, “outlook”, “guidance”, “forecasts”, “may”, “will”, “would”, “could” or “should” or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors because they relate to events and depend on circumstances that may or may not occur in the future and may be beyond the Company’s ability to control or predict which may cause the actual results or performance of the Company to be materially different from the results or performance expressed or implied by such forward-looking statements. Forward looking statements are based on assumptions and are not guarantees or predictions of future performance. No representation is made that any of these statements or projections will come to pass or that any forecast result will be achieved, nor as to their accuracy, completeness or correctness. Similarly, no representation is given that the assumptions upon which forward looking statements may be based are reasonable.



RACURA ONCOLOGY

# Corporate snapshot

Racura Oncology is an ASX-listed, late-stage clinical biopharmaceutical company

## Key metrics ($A)

| | |
|---|---|
| ASX code | RAC |
| Share price | $2.09[1] |
| Market capitalisation | $409.8m[1] |
| Cash at bank | $34.3m[2] |
| Debt | Nil |
| Enterprise value | $375.5m[1] |
| Shares on issue | 196,068,940[1] |
| Options on issue | 10,201,193[1] |

1. *As at 27 July 2026*
2. *As at 30 June 2026*

## Racura 12-month trading history[1]


## Current funding

- **On 29 May 2026, Racura concluded a fully underwritten option issue and intuitional placement which has provided an additional $17.8m million since 31 March 2026**
- **Racura is fully funded to undertake all trials and other programs into 2028 from existing funds**



RACURA ONCOLOGY

# Why invest in Racura Oncology?

## Investment opportunity for Racura has fundamentally changed in recent times

### Clinically validated drug
Bisantrene used in >50 clinical trials. Established safety and anticancer activity.

### Improved drug - RC220
Reformulated for better administration. 20 years of patent protection.

### 20yr composition of matter patent filed
Covers the active isomer, (E,E)-bisantrene discovered by Racura research team.

### G4-DNA & RNA binder
MOA identified to be G4-DNA & RNA binding. Targets the key cancer growth regulator MYC.

### Many value drivers
Significant news flow throughout 2026 & 2027. Three open label clinical trials reporting.

### Investor & patient focused
Ethos, communication and funding strategies.



RACURA ONCOLOGY

# MYC: Oncology's largest untapped opportunity

## Treating MYC dysregulation is a huge opportunity across numerous cancer types

**70%** **of all cancers have elevated MYC activity**

### MYC is a potent accelerator of cancer growth

- ✓ Discovered in 1982
- ✓ Controls genes involved in cell growth

### Difficult to target - considered undruggable

- ✓ No conventional binding pocket as protein is unstructured
- ✓ No clinically effective MYC inhibitors even after decades of research

### Broad oncology applicability

- ✓ Elevated MYC across multiple tumour types
- ✓ More than 1 million new cancers each year in the USA

## Major cancers with elevated MYC activity[1]




**MYC inhibition has broad clinical and commercial value across most cancer**



1. Data from TCGA and Schaub et al., 2018, Cell Systems 6, 282–300.

RACURA ONCOLOGY

# (E,E)-bisantrene

## Binds and stabilises G-quadruplex DNA, silencing the c-MYC oncogene[1]

### G-quadruplexes or G4

Key regulatory structures in DNA (& RNA) recognised by transcription and translation factors to regulate cell growth and division



Double stranded DNA (double helix)



G-quadruplex (G4) DNA



1. Racura Oncology (ASX Announcement 02 Oct 2025)



RACURA ONCOLOGY

# Scientific support for c-MYC gene silencing activity

(E,E)-bisantrene stabilises MYC G-quadruplex (G4) and turns off expression of c-MYC gene




**G4 Melting**

Bisantrene stabilises c-MYC G4



**Molecular Dynamics**

Predicts binding of bisantrene to c-Myc G4




**Surface Plasmon Resonance**

Measures affinity of bisantrene for c-MYC G4



**$^{1}$H-NMR**

Shows how bisantrene binds to c-MYC G4



**Gene Expression Analysis**

Consistent downregulation of MYC regulated genes






G4, G-quadruplex; $^{1}$H-NMR, proton nuclear magnetic resonance

RACURA ONCOLOGY

# MYC inhibitors in the clinic

## RC220 competitors are all at early stage and have limited clinical activity

| Drug | Developer | Mechanism of action | Clinical activity |
|---|---|---|---|
| **MYC Direct (protein/gene)** | | | |
| RC220 | Racura Oncology | G-quadruplex stabiliser | Phase 3 AML, Phase 1 NSCLC, Phase 1 solid tumours; 40% CR/PR in AML |
| OMO-103 | Peptomyc S.L. | MYC-MAX inhibitor (Omomyc miniprotein) | Phase 2 (osteosarcoma); 8/22 SD, no CR or PR |
| IDP-121 | IDP-Pharma | Stapled peptide direct inhibitor of MYC | Phase 1/2 in MM; No clinical efficacy data released |
| PC-002 | Cothera Bio | De-ubiquitinase inhibitor | Phase 2 lymphoma; 1/13 CR, no PR |
| LMP744 | Gibson Oncology | G-quadruplex stabiliser | Phase 1/2 GBM; 2/40 PR, no CR |
| CX-5461 | Senhwa Biosciences | G-quadruplex stabiliser | Phase 1b BRCA1/2 or HR deficient solid tumours; 4/40 PR, 11/40 SD |
| WBC100 | Hangzhou Weben | MYC-specific PROTAC degrader | Phase 1 in MYC+ solid tumours; No clinical efficacy release |
| **Other pathways** | | | |
| WP1066 | Moleculin Biotech | p-STAT3 inhibitor (impacts MYC transcription) | Phase 2 GBM with radiotherapy |
| GP2250 | Persevere Tx | Inhibits MYC and NFκB | Phase 1 pancreatic |
| PMR-116 | Pimera Tx/ ANU | Inhibits pathway downstream of MYC | Phase 1 in MYC+ solid tumours |



Source www.clinicaltrials.gov, company websites and announcements

RACURA
ONCOLOGY

# Clinical Programs

# Clinical pipeline

## Three clinical programs in AML, lung cancer and solid tumours

| Cancer indication | Total addressable patients[1] | Phase 1 | Phase 2 | Phase 3 | Comment |
|---|---|---|---|---|---|
| **AML**<br>Acute myeloid leukaemia[2] | US/EU: 50,000 | **Phase 3** | | | 40% response rate in two Phase 2 trials[3]<br>Bisantrene approved in 1988 in France |
| **EGFRm lung cancer**<br>EGFR Non-small lung cancer (NSCLC) in combination with osimertinib (TKI)[2] | China: 445,000<br>US/EU: 95,000 | **Phase 1** | | | Osimertinib 2025 sales >US$7.2 billion[4] |
| **CPACS**<br>Cardioprotection & anticancer synergy in combination with doxorubicin in solid tumours[5] | Global: 4 million | **Phase 1** | | | Patients have been safely dosed with RC220 and RC220+Dox[5] |

1. Estimated number of patient per year for each indication. US – USA & Canada; EU - Europe
2. ASX Announcement (17 Nov 2025)
3. ASX Announcement (30 Jul 2024)
4. AstraZeneca Annual Report 2025; Jannsen Annual Report 2025; Hansoh Annual Report 2025; Shanghai Allist Annual report 2025
5. ASX Announcement (20 Oct 2025)



RACURA ONCOLOGY

# Shared mechanism, multiple pathways to market

## RC220's shared MYC mechanism supports multiple oncology programs

RACURA ONCOLOGY

**RC220**

### Program 1: Acute myeloid leukaemia (EMILI)

**Phase 3**

*Monotherapy*

**US$3.5B+**

Global AML market size (2024)

MYC represents the lead validation pathway for RC220's MYC-targeting mechanism

***Clinical foundation for all programs. Provides early MYC data insights.***

### Program 2: EGFRm lung cancer (HARNESS)

**Phase 1**

*In combination with osimertinib (Tagrisso)*

**US$7.2B+**

Global osimertinib annual sales (2025)

MYC-mediated resistance emerges following osimertinib (AstraZeneca's top selling cancer drug) treatment – supporting combination potential

***MYC involved in resistance to many other drug classes.***

### Program 3: Cardioprotection & anticancer (CPACS)

**Phase 1**

*In combination with doxorubicin*

**US$1.5B+**

Global doxorubicin (generic) market size

Anthracyclines remain widely used oncology backbones, but cardiotoxicity limits treatment intensity – RC220 aims to improve anthracycline anticancer activity and provide cardioprotection

***RC220 reduces doxorubicin toxicity, enabling more doses to be given.***

**Key takeaway**

**MYC dysregulation is implicated across all three target pathways, supporting broader applicability of RC220**



RACURA ONCOLOGY

# Extreme value from clinical success with difficult targets

RAS provides a compelling precedent for MYC – value of success with major "undruggable" targets

| Company | Target | Stage at peak (all pre-revenue) | | | | Peak market value | Outcome/ Status |
|---|---|---|---|---|---|---|---|
| | | 1/1b | 2 | 3 | Approved | | |
| MIRATI THERAPEUTICS® | KRAS G12C | | | | | US$12B | 2023 - Acquired for $US4.8bn +$1bn earn out<br>Bristol Myers Squibb |
| Revolution Medicines | Pan-RAS / KRAS | | | | | US$40B | 2026 - Takeover speculation |
| ERASCA™ | Pan-RAS / KRAS | | | | | US$6B | 2026 - Raised US$260m |

**Key takeaway**

RAS was undruggable for decades – changing this has generated significant value

**RC220 is the only clinically efficacious MYC-targeting drug and is at Phase 3**



RACURA ONCOLOGY

# Multiple clinical and strategic catalysts through 2027

## Upcoming milestones across AML, NSCLC, cardioprotection and mechanism validation




**1H26**

- ✓ MYC mechanism of action presented at AACR conference
- ✓ CPACS dose escalation update released
- ✓ First patient dosed in HARNESS-1 lung cancer trial

**2H26**

- Phase 3 CMC manufacturing program initiated
- Early efficacy signal from HARNESS-1 trial
- RC220 combination data expansion (preclinical)
- Phase 3 AML trial initiated (Part A - dose optimisation)
- US IND filed for Phase 3 AML trial

**2027**

- HARNESS-1 proof-of-concept clinical data
- First human cardioprotective efficacy data (CPACS)
- HARNESS-1 FDA Project Optimus stage initiated
- CPACS Phase 2 trial initiated
- Phase 3 AML expansion stage initiated (Part B)
- Mechanism of Action published in peer-reviewed journal



1. All dates are estimates and subject to change

RACURA ONCOLOGY

# Contact


DANIEL TILLETT
CEO & MD
+61 2 8051 3043
daniel.tillett@racuraoncology.com

JANE LOWE
Investor & Media Relations
+61 411 117 774
jane.lowe@irdepartment.com.au